AVITA Medical, Inc. (RCEL) Insider Trading Activity

NASDAQ$3.41
Market Cap
$91.37M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
209 of 826
Rank in Industry
27 of 108

RCEL Insider Trading Activity

RCEL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$326,010
8
100
Sells
$0
0
0

Related Transactions

McNamara Robertdirector
4
$287,200
0
$0
$287,200
O'Toole David DCFO
4
$38,810
0
$0
$38,810

About AVITA Medical, Inc.

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.

Insider Activity of AVITA Medical, Inc.

Over the last 12 months, insiders at AVITA Medical, Inc. have bought $326,010 and sold $0 worth of AVITA Medical, Inc. stock.

On average, over the past 5 years, insiders at AVITA Medical, Inc. have bought $158,551 and sold $218,215 worth of stock each year.

Highest buying activity among insiders over the last 12 months: McNamara Robert (director) — $287,200. O'Toole David D (CFO) — $38,810.

The last purchase of 10,000 shares for transaction amount of $45,000 was made by McNamara Robert (director) on 2025‑08‑28.

List of Insider Buy and Sell Transactions, AVITA Medical, Inc.

2025-08-28PurchaseMcNamara Robertdirector
10,000
0.0386%
$4.50
$45,000
-8.90%
2025-08-26PurchaseO'Toole David DCFO
2,000
0.007%
$4.52
$9,040
-12.06%
2025-08-19PurchaseMcNamara Robertdirector
10,000
0.0385%
$5.00
$50,000
-14.89%
2025-08-12PurchaseO'Toole David DCFO
2,000
0.0076%
$4.81
$9,620
-23.73%
2025-03-06PurchaseMcNamara Robertdirector
11,000
0.0415%
$8.30
$91,300
-33.98%
2025-02-20PurchaseMcNamara Robertdirector
10,000
0.0375%
$10.09
$100,900
-44.57%
2025-02-20PurchaseO'Toole David DCFO
1,000
0.0037%
$9.90
$9,900
-44.57%
2025-02-19PurchaseO'Toole David DCFO
1,000
0.0038%
$10.25
$10,250
-45.99%
2024-12-09PurchaseCrowe Suzannedirector
486
0.0018%
$13.15
$6,391
-56.68%
2024-12-05PurchaseO'Toole David DCFO
975
0.0037%
$12.46
$12,152
-51.89%
2024-05-30PurchaseO'Toole David DCFO
1,000
0.0037%
$8.90
$8,900
+0.75%
2024-02-28PurchaseO'Toole David DCFO
1,250
0.005%
$17.39
$21,738
-41.55%
2023-12-26SaleCORBETT JAMESCEO
1,445
0.0057%
$13.29
$19,204
-23.39%
2023-12-21SaleCOOK JEREMY CURNOCKdirector
2,500
0.01%
$12.49
$31,225
-16.85%
2023-12-13SaleCOOK JEREMY CURNOCKdirector
2,518
0.0095%
$12.27
$30,896
-20.24%
2023-12-12PurchaseO'Toole David DCFO
950
0.0039%
$12.45
$11,828
-14.71%
2023-12-01PurchaseO'Toole David DCFO
500
0.0019%
$10.68
$5,340
-7.12%
2023-11-21PurchaseO'Toole David DCFO
2,000
0.008%
$10.28
$20,560
+2.90%
2023-11-16PurchaseO'Toole David DCFO
1,000
0.0038%
$12.15
$12,150
-17.17%
2023-11-15PurchaseO'Toole David DCFO
2,000
0.0078%
$12.85
$25,700
-19.20%
Total: 37
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
McNamara Robertdirector
86771
0.3238%
$295,889.1140
O'Toole David DCFO
31657
0.1181%
$107,950.37170
<0.0001%
PERRY MICHAEL SChief Executive Officer
321712
1.2006%
$1.1M08
Shiroma DonnaGeneral Counsel
42257
0.1577%
$144,096.3701
Crowe Suzannedirector
36912
0.1378%
$125,869.9220
<0.0001%
COOK JEREMY CURNOCKdirector
20614
0.0769%
$70,293.7402
CORBETT JAMESCEO
11580
0.0432%
$39,487.8001
McIntyre DavidChief Financial Officer
893
0.0033%
$3,045.1320
<0.0001%
*Gray background shows insiders who have made transactions during last year

RCEL Institutional Investors: Active Positions

Increased Positions27+22.31%564,860+7.3%
Decreased Positions54-44.63%3M-40.3%
New Positions14New293,043New
Sold Out Positions19Sold Out867,101Sold Out
Total Postitions94-22.31%5M-33.01%

RCEL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$4,725.004.55%1.37M-84,890-5.85%2025-09-30
Blackrock, Inc.$3,939.003.8%1.14M-757,219-39.95%2025-09-30
State Street Corp$1,465.001.41%423,308-105,476-19.95%2025-09-30
Geode Capital Management, Llc$1,147.001.11%331,463-286,879-46.4%2025-09-30
Northern Trust Corp$598.000.58%172,778-86,819-33.44%2025-09-30
Millennium Management Llc$459.000.44%132,709-236,483-64.05%2025-09-30
Aqr Capital Management Llc$413.000.4%119,288+97,365+444.12%2025-09-30
Bridgeway Capital Management, Llc$408.000.39%118,004+80,404+213.84%2025-09-30
Goldman Sachs Group Inc$404.000.39%116,845+23,190+24.76%2025-09-30
Divisadero Street Capital Management, Lp$346.000.33%100,000+100,000New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.